-
2022-502889-24-00
5
2024-02-13
chemotherapy-induced polyneuropathy (CIPN)
-
2022-500531-36-00
4
2024-02-02
Type 1 diabetes mellitus
-
2023-506572-27-00
3
2024-01-12
Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD)
-
2024-512881-32-00
6
2023-11-22
Psoriasis vulgaris and/or psoriatric arthritis
-
2023-503224-66-00
5
2023-10-31
Atrial Fibrillation
-
2023-503582-35-00
6
2023-10-26
Staphylococcus aureus bacteremia
-
2023-503558-10-00
5
2023-10-13
oligometastatic pancreatic cancer
-
2022-502160-20-00
5
2023-10-02
Idiopathic Immune Complex Mediated Membranoproliferative Glomeruloneph
-
2022-503081-74-00
5
2023-09-05
Cystic Fibrosis
-
2022-501797-19-00
1
2023-07-13
Acute Myeloid Leukemia (AML)
-
2024-517966-40-00
4
2023-07-13
Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::ABL1 positive (Ph
-
2022-501943-34-00
5
2023-06-27
Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
-
2024-512878-98-00
9
2023-05-16
Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative
Breas
-
2023-504861-22-00
4
2023-05-05
Pulmonary arterial hypertension
-
2022-501238-52-00
10
2023-03-23
Heart failure due to systemic left ventricular systolic dysfunction
-
2024-513754-29-00
5
2023-03-06
Cystic Fibrosis
-
2022-501090-39-00
5
2022-12-14
Biliary Atresia
-
2022-500783-35-00
5
2022-12-06
Acute Myeloid Leukemia
-
2024-514180-25-00
5
2022-11-21
unresectable or metastatic HER2+ colorectal cancer
-
2023-508389-13-00
5
2022-11-08
Combined endpoint of all-cause mortality, kidney failure, and hospital
-
2023-504885-50-00
5
2022-11-07
Treatment of children with chronic kidney disease and proteinuria
-
2023-508425-28-00
4
2022-10-24
Chronic Inflammatory Demyelinating Polyneuropathy
-
2022-500764-35-00
6
2022-10-13
Patients with advanced HER2-negative, hormone receptor positive (HER2n
-
2022-500107-50-00
6
2022-10-12
hilar cholangiocarcinoma